Literature DB >> 16758510

Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years.

Arvind Rajasekaran1, David Shovlin, Vadivelu Saravanan, Philip Lord, Clive Kelly.   

Abstract

OBJECTIVE: There is little information on the natural history of patients with rheumatoid arthritis (RA) and associated interstitial lung disease (ILD). Cryptogenic fibrosing alveolitis (CFA) is known to have a poor longterm prognosis, and we compared the 2 conditions through a longitudinal prospective study.
METHODS: We previously compared baseline clinical, physiological, and radiological characteristics in 18 RA-ILD patients with 18 case controls with CFA. Clinical, physiological, and radiological assessment was repeated in all survivors at 5 years, and data on treatment and mortality were collected.
RESULTS: The median age in each group was 77 years and 10 patients in each group were male. More patients with RA-ILD survived to 5 years (8 RA-ILD vs 2 CFA; p = 0.03), and median survival was significantly longer for patients with RA-ILD (60 mo) compared to CFA (27 mo; p <or= 0.05). Death was due to respiratory failure in half the patients with CFA, but was more often due to other causes in patients with RA. Clubbing and reduced baseline gas transfer were predictors of poor prognosis, while normal technetium clearance enhanced survival in nonsmokers.
CONCLUSION: Patients with RA-ILD did better than those with CFA, and died less often from respiratory failure. Patients with finger clubbing and/or low gas transfer declined more rapidly.

Entities:  

Mesh:

Year:  2006        PMID: 16758510

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.

Authors:  Tim Bongartz; Carlotta Nannini; Yimy F Medina-Velasquez; Sara J Achenbach; Cynthia S Crowson; Jay H Ryu; Robert Vassallo; Sherine E Gabriel; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2010-06

2.  Interstitial lung disease in rheumatoid arthritis.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

Review 3.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 4.  Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts.

Authors:  Yoel Brito; Marilyn K Glassberg; Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2017-11-09       Impact factor: 4.592

Review 5.  Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.

Authors:  Eunice J Kim; Harold R Collard; Talmadge E King
Journal:  Chest       Date:  2009-11       Impact factor: 9.410

6.  Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma.

Authors:  Mark J Hamblin; Maureen R Horton
Journal:  Pulm Med       Date:  2011-06-04

7.  Interstitial Lung Disease of the UIP Variant as the Only Presenting Symptom of Rheumatoid Arthritis.

Authors:  Abhinav Agrawal; Braghadheeswar Thyagarajan; Sidney Ceniza; Syed Hasan Yusuf
Journal:  Case Rep Pulmonol       Date:  2015-06-07

Review 8.  Rheumatoid arthritis-associated interstitial lung disease.

Authors:  Joshua J Solomon; Kevin K Brown
Journal:  Open Access Rheumatol       Date:  2012-03-05

Review 9.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors:  Shunsuke Mori
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.